[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,868,592
  • Shares Outstanding, K 102,955
  • Annual Sales, $ 14,343 M
  • Annual Income, $ 4,505 M
  • EBIT $ 3,843 M
  • EBITDA $ 4,387 M
  • 60-Month Beta 0.22
  • Price/Sales 5.93
  • Price/Cash Flow 19.69
  • Price/Book 2.68

Options Overview Details

View History
  • Implied Volatility 27.12% (-0.33%)
  • Historical Volatility 29.58%
  • IV Percentile 4%
  • IV Rank 5.00%
  • IV High 49.01% on 10/10/25
  • IV Low 25.96% on 08/14/26
  • Expected Move (DTE 3) 15.98 (1.93%)
  • Put/Call Vol Ratio 0.97
  • Today's Volume 1,180
  • Volume Avg (30-Day) 2,080
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 36,362
  • Open Int (30-Day) 40,666
  • Expected Range 812.52 to 844.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $12.89
  • Number of Estimates 6
  • High Estimate $15.06
  • Low Estimate $9.58
  • Prior Year $9.63
  • Growth Rate Est. (year over year) +33.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
659.53 +25.62%
on 07/27/26
847.00 -2.18%
on 08/21/26
+172.49 (+26.29%)
since 07/24/26
3-Month
591.52 +40.06%
on 06/02/26
847.00 -2.18%
on 08/21/26
+189.62 (+29.68%)
since 05/22/26
52-Week
541.00 +53.14%
on 10/13/25
847.00 -2.18%
on 08/21/26
+239.02 (+40.55%)
since 08/22/25

Most Recent Stories

More News
Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP

SAN FRANCISCO , Aug. 24, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN)  that a securities class action lawsuit has been filed...

REGN : 828.50 (-0.66%)
REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals Securities Class Action - Contact SueWallSt

This Regeneron analyst reaction focuses on analysts' reassessment of the Phase III Fianlimab-Libtayo Study after a protocol amendment raised concerns about statistical significance and potential impact...

REGN : 828.50 (-0.66%)
REGN Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regeneron Pharmaceuticals Securities Lawsuit - Contact Levi & Korsinsky

Ryan Crowe Regeneron securities defendant liability allegations focus on investor-facing statements about the Phase III Fianlimab-Libtayo Study before REGN shares declined $102.09 per share from the Class...

REGN : 828.50 (-0.66%)
Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit

SAN FRANCISCO , Aug. 20, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN)  that a securities class action lawsuit has been filed...

REGN : 828.50 (-0.66%)
REGN Stockholders Interested in Leading the Class Action Against Regeneron Pharmaceuticals, Inc. Should Contact Robbins LLP for Information About Recovering Their Losses

SAN DIEGO , Aug. 19, 2026 /PRNewswire/ -- Robbins LLP  reminds investors that a securities class action has been filed on behalf of investors who purchased or otherwise acquired Regeneron...

REGN : 828.50 (-0.66%)
Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:  REGN ) will webcast management participation as follows: 2026 Wells Fargo Healthcare Conference at 8:45...

REGN : 828.50 (-0.66%)
Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans...

FOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability  Approval...

REGN : 828.50 (-0.66%)
REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Notice - Contact Levi & Korsinsky

Market impact notice: REGN shares allegedly lost $102.09 from the Class Period high after disclosures about a Phase III Fianlimab-Libtayo protocol change and failed primary endpoint challenged...

REGN : 828.50 (-0.66%)
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

NEW YORK , Aug. 18, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).

REGN : 828.50 (-0.66%)
Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP

SAN FRANCISCO , Aug. 18, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN)  that a securities class action lawsuit has been filed...

REGN : 828.50 (-0.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 845.63
2nd Resistance Point 840.16
1st Resistance Point 834.33
Last Price 828.50
1st Support Level 823.03
2nd Support Level 817.56
3rd Support Level 811.73

See More

52-Week High 847.00
Last Price 828.50
Fibonacci 61.8% 730.11
Fibonacci 50% 694.00
Fibonacci 38.2% 657.89
52-Week Low 541.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.